INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $18.40.

Several research analysts have recently commented on INMB shares. Maxim Group decreased their price objective on INmune Bio from $30.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, July 2nd. Scotiabank reaffirmed a “sector underperform” rating on shares of INmune Bio in a research note on Tuesday, July 1st. Raymond James Financial downgraded INmune Bio from a “moderate buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of INmune Bio in a research note on Tuesday, July 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INMB. PFG Investments LLC bought a new position in INmune Bio in the 2nd quarter worth approximately $27,000. Wells Fargo & Company MN increased its stake in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after acquiring an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC bought a new stake in INmune Bio in the 4th quarter worth approximately $48,000. Quarry LP bought a new stake in INmune Bio in the 1st quarter worth approximately $48,000. Finally, JPMorgan Chase & Co. increased its stake in INmune Bio by 93.0% in the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock worth $53,000 after acquiring an additional 5,461 shares during the last quarter. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Stock Down 15.2%

NASDAQ INMB opened at $2.68 on Friday. The stock’s 50-day moving average price is $5.05 and its 200-day moving average price is $6.94. INmune Bio has a 52 week low of $1.89 and a 52 week high of $11.64. The company has a market capitalization of $63.19 million, a P/E ratio of -1.39 and a beta of 1.34.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $0.05 million during the quarter. Research analysts anticipate that INmune Bio will post -2.24 EPS for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.